Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Benfotiamine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
7 of 7 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Benfotiamine and Potassium have evidence — compare verdict strength side-by-side.
150-600mg daily
With meals
Benfotiamine capsules
99-500mg daily from supplements (food provides more)
With food to reduce GI upset, Spread throughout day, During/after exercise for athletes
Potassium Citrate or Potassium Gluconate
4-12 weeks
8-12 weeks
2-4 weeks
1-2 weeks
Long-term
With excess or kidney issues
Vitamin B and its derivatives for diabetic kidney disease
The Cochrane database of systematic reviews (2015) · Meta analysis · n=1354
There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
BMJ open (2022) · Meta analysis · n=364
There was a significant increase in high-density lipoprotein (HDL) (MD, 0.10; 95% CI: 0.10 to 0.20) at 3-month follow-up.
Therapeutic potential of benfotiamine and its molecular targets
European review for medical and pharmacological sciences (2018) · Systematic review
The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes.
Effect of changes in potassium intake on blood pressure: a dose–response meta-analysis of randomized clinical trials (2000–2024)
Clinical Kidney Journal (2025) · Meta analysis · n=2500
Dose-response analysis of RCTs from 2000-2024
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Nutrients (2024) · Meta analysis
Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations.
Sex-specific associations between sodium and potassium intake and overall and cause-specific mortality: a large prospective U.S. cohort study, systematic review, and updated meta-analysis of cohort studies
BMC medicine (2024) · Meta analysis · n=237036
Meta-analysis examining Potassium efficacy
Limited RCT data with mixed results. Meta-analysis found insufficient evidence to determine clear benefit. Conservative estimates based on subset of positive trials showing modest improvements in neuropathic symptoms.
AI-estimated from published studies. Interpret as directional guidance.
Benfotiamine has a higher evidence score (5.5/10 vs 8.5/10) and wins in 2 of 3 categories.
For reduce inflammation, Potassium has a higher relevance score (85 vs 75).
No known interactions between Benfotiamine and Potassium have been documented in our database. However, always consult a healthcare provider before combining supplements.